Talecris Biotherapeutics raised $600 million by selling senior notes, two weeks after the company brought in $950 million in its initial public offering of stock.
The Research Triangle Park company will use the latest financing to repay existing, more expensive loans.
Talecris is bolstering its balance sheet as officials consider where to expand production of medicines made from blood plasma. Executives could choose to add capacity and hundreds of more jobs at a massive Clayton facility but have said they're also looking at new sites.
Assistant Business Editor Alan M. Wolf joined the N&O in 1999 covering the business of health care. He became an editor in 2001, and helps oversee the paper's daily business coverage and Sunday Work&Money section. He lives in Clayton with his wife and two children. Reach him at 919-829-4572 or 
Comments
Re: Talecris raises $600 million in debt sale
Sat, 10/17/2009 - 05:14 — TyshawnRepublican are in depressed economic situation, they have no choice but seek for a financial support. Just about everyone has gotten installment loans at one point or another. Think you haven’t? You think that only means short term installment loans, or payday loans right? Well guess what Shirley – if you've ever got a loan that you pay back in installments, you've gotten one. If you've financed a car, a house, or a college education, you've borrowed installment loans. That's all that's meant, even installment loans for bad credit – it means you pay it back with more than one payment. Chances are that if you've ever been borrowing money in any form whatsoever, it's been with installment loans of some sort.